Reports

Drug name	NICE TAs	Comments
Everolimus (Afinitor®)	TA432 - Everolimus for advanced renal cell carcinoma after previous treatment TA498 - Lenvatinib with everolimus for previously treated advanced renal cell carcinoma TA449 - Everolimus and sunitinib for treating unresectable or metastatic neuroendocrine tumours in people with progressive disease TA421 - Everolimus with exemestane for treating advanced breast cancer after endocrine therapy	Negative outcome - CDF funded for renal, NET, breast. For hospital use only.
Evolocumab	TA394 - Evolocumab for treating primary hypercholesterolaemia and mixed dyslipidaemia & Homozygous familial hypercholesterola EMIA in line with NHS England SSC 1649	To be used in line with NICE TA
Exemestane tablets	TA112 - Hormonal therapies for the adjuvant treatment of early oestrogen-receptor-positive breast cancer
Exenatide prolonged release injection (Bydureon®)	NICE NG28: Type 2 diabetes in adults - management
Ezetimibe tablets	TA132 - Ezetimibe for the treatment of primary (heterozygous-familial and non-familial) hypercholesterolaemia
Febuxostat tablets	TA164 - Febuxostat for the management of hyperuricaemia in people with gout
Fedratinib (Inrebic®)	TA756 - Fedratinib for treating disease-related splenomegaly or symptoms in myelofibrosis
Fenfluramine	TA808 - Fenfluramine for treating seizures associated with Dravet syndrome
Ferric maltol (Feraccru®)	RICaD for Ferric maltol (pdf)	For the treatment of iron deficiency anaemia (IDA) in patients with inflammatory bowel disease (IBD), unable to tolerate other oral iron formulations. Supported by a RICaD
Filgotinib (Jyseleca®)	TA676 - Filgotinib for treating moderate to severe rheumatoid arthritis

First page
Previous page
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
Next page
Last page

University Hospitals Birmingham NHS Foundation Trust

Medicines Formulary

Reports